Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen

Daniel A. Goldstein

doi:10.1001/jamaoncol.2017.3123

Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen

Daniel A. Goldstein

Rabin Medical Center Israel

Research output: Contribution to journal › Editorial

12 Scopus citations

Original language	English
Pages (from-to)	1628-1629
Number of pages	2
Journal	JAMA Oncology
Volume	3
Issue number	12
DOIs	https://doi.org/10.1001/jamaoncol.2017.3123
State	Published - 1 Dec 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jamaoncol.2017.3123

Cite this

@article{5cf825b2c9c545a89a7d8037fc3d4930,

title = "Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen",

author = "Goldstein, {Daniel A.}",

year = "2017",

month = dec,

day = "1",

doi = "10.1001/jamaoncol.2017.3123",

language = "אנגלית",

volume = "3",

pages = "1628--1629",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "12",

}

TY - JOUR

T1 - Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen

AU - Goldstein, Daniel A.

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85044363468&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2017.3123

DO - 10.1001/jamaoncol.2017.3123

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 28983562

AN - SCOPUS:85044363468

SN - 2374-2437

VL - 3

SP - 1628

EP - 1629

JO - JAMA Oncology

JF - JAMA Oncology

IS - 12

ER -

Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen

UN SDGs

Access to Document

Other files and links

Cite this